<DOC>
	<DOC>NCT00404833</DOC>
	<brief_summary>This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental glomerulosclerosis (FSGS). The change in urine protein excretion will be the primary outcome studied. The treatment regimen comprising prednisolone and mycophenolate mofetil will be compared with prednisolone and chlorambucil in MN, and compared with prednisolone in FSGS. The study duration will be 12 months for each patient.</brief_summary>
	<brief_title>Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>abnormal urine protein excretion and biopsyproven idiopathic membranous nephropathy or focal segmental glomerulosclerosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>idiopathic membranous nephropathy or focal segmental glomerulosclerosis</keyword>
</DOC>